TME Pharma N.V. (FR:ALTME)
:ALTME
Top Page
TME Pharma N.V.
(ALTME)
Select Model
Select Model
Rating:47Neutral
Price Target:
€0.07
▲(18.33% Upside)
Action:ReiteratedDate:01/31/26
The score is primarily constrained by weak financial performance, including persistent losses and negative cash flows. Technical indicators provide some near-term support (positive MACD and price above 20/50-day averages), but longer-term trends are still unfavorable. Valuation is also a headwind because the negative P/E reflects ongoing losses and there is no dividend yield data to offset risk.
Positive Factors
Low leverage on balance sheet
A debt-to-equity ratio of 0.03 gives TME Pharma low interest burden and greater financing flexibility. For a clinical-stage biotech that will rely on external funding, limited leverage reduces near-term refinancing risk and preserves capacity to raise equity or partner funding to progress trials.
Negative Factors
Persistently negative margins and losses
Sustained negative gross and net margins indicate the company is not yet operationally profitable. Persistent losses force continuous external funding, increase dilution risk, and limit reinvestment capacity, constraining TME Pharma's ability to self-fund trials or scale without partner financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage on balance sheet
A debt-to-equity ratio of 0.03 gives TME Pharma low interest burden and greater financing flexibility. For a clinical-stage biotech that will rely on external funding, limited leverage reduces near-term refinancing risk and preserves capacity to raise equity or partner funding to progress trials.
Read all positive factors
TME Pharma N.V. (ALTME) vs. iShares MSCI France ETF (EWQ)
Market Cap
€6.66M
Dividend YieldN/A
Average Volume (3M)547.76K
Price to Earnings (P/E)―
Beta (1Y)-0.29
Revenue GrowthN/A
EPS GrowthN/A
CountryFR
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding94,188,980
10 Day Avg. Volume795,319
30 Day Avg. Volume547,758
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.27
Price to Sales (P/S)107.95
P/FCF Ratio-0.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.15
Revenue Forecast (FY)N/A
TME Pharma N.V. Business Overview & Revenue Model
Company Description
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, in...
How the Company Makes Money
TME Pharma generates revenue primarily through collaborations and partnerships with pharmaceutical companies, as well as potential licensing agreements for its drug candidates. The company may also receive milestone payments tied to the successful...
TME Pharma N.V. Financial Statement Overview
Summary
Income Statement
20
Very Negative
Balance Sheet
30
Negative
Cash Flow
25
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 46.00K | 19.00K | 17.00K | 0.00 | 33.00K | 35.00 |
| Gross Profit | -12.00K | -78.00K | -127.00K | -92.00K | -65.97K | -62.97K |
| EBITDA | -4.38M | -5.25M | -5.07M | -11.63M | -12.88M | -5.29M |
| Net Income | -4.58M | -5.72M | -6.74M | -15.13M | -14.45M | -10.40M |
Balance Sheet | ||||||
| Total Assets | 2.29M | 3.41M | 2.49M | 5.24M | 9.77M | 10.65M |
| Cash, Cash Equivalents and Short-Term Investments | 2.06M | 3.25M | 2.25M | 4.63M | 9.48M | 10.30M |
| Total Debt | 1.89M | 56.00K | 1.17M | 4.09M | 2.44M | 653.00K |
| Total Liabilities | 2.86M | 1.79M | 2.79M | 6.51M | 5.27M | 2.96M |
| Stockholders Equity | -570.00K | 1.61M | -294.00K | -1.27M | 4.51M | 7.71M |
Cash Flow | ||||||
| Free Cash Flow | -4.77M | -4.65M | -5.65M | -12.16M | -12.39M | -5.26M |
| Operating Cash Flow | -4.76M | -4.63M | -5.63M | -12.14M | -12.38M | -5.22M |
| Investing Cash Flow | -5.00K | -21.00K | -19.00K | -21.00K | -14.00K | -39.00K |
| Financing Cash Flow | 4.13M | 5.66M | 3.27M | 7.29M | 11.50M | 14.18M |
TME Pharma N.V. Technical Analysis
Negative
0.06
Price Trends
0.07
Negative
0.07
Positive
0.09
Negative
Market Momentum
>-0.01
Positive
45.75
Neutral
47.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALTME, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.07, and below the 200-day MA of 0.09, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.75 is Neutral, neither overbought nor oversold. The STOCH value of 47.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALTME.
TME Pharma N.V. Peers Comparison
UnderperformOutperform
Sector (51)
FR:ALTME
TME Pharma N.V.
0.07
<0.01
2.94%
GB:0NWK
Valerio Therapeutics
0.12
0.07
116.07%
DE:3HB
Hybrigenics SA Class A
―
―
―
DE:3VG
Theranexus SA
3.07
2.69
710.03%
FR:ALPAT
Plant Advanced Technologies SA
7.48
-1.52
-16.89%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.